Evogene Ltd. filed a Form 6-K on November 19, 2026, disclosing management changes including the appointment of Dr. Adi Zuluf-Shani as Chairperson of the Board and the replacement of its VP Finance, effective November 22, 2026.

Key Highlights

  • New Board Chairperson: Dr. Adi Zuluf-Shani was appointed Chairperson of the Board as of November 18, 2026.
  • VP Finance resignation: Ms. Polina Ravzin notified her resignation as VP Finance, effective November 22, 2026, cited as being due to personal reasons.
  • No disagreement stated: According to the filing, the resignation "was not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company."
  • New VP Finance appointed: Mr. Rephael Haim was appointed VP Finance, effective November 22, 2026.
  • Haim's prior roles: Before joining Evogene, Mr. Haim served as Head of Financial Planning and Analysis at Nanox Imaging (NASDAQ:NNOX) and as VP Finance and Head of FP&A at Questar Auto Technologies.
  • Prior Evogene tenure: The filing notes that Mr. Haim also served as a controller at Evogene Ltd. during 2019-2022.

Evogene Reports Board and Finance Leadership Changes in November 2026

Evogene Ltd. (NASDAQ:EVGN), an Israeli-based company, submitted a Form 6-K to the U.S. Securities and Exchange Commission on November 19, 2026, reporting two distinct management changes. The company's Board of Directors appointed Dr. Adi Zuluf-Shani as Chairperson of the Board, effective November 18, 2026, according to the filing.

Separately, the filing disclosed that Ms. Polina Ravzin, who held the position of VP Finance, submitted her resignation effective November 22, 2026. The company stated the departure was due to personal reasons and explicitly noted it was not related to any disagreement with the company concerning its operations, policies, or practices. To fill the vacancy, Evogene appointed Mr. Rephael Haim as the new VP Finance, also effective November 22, 2026.

According to the filing, Mr. Haim brings prior experience from Nanox Imaging, where he served as Head of Financial Planning and Analysis, and from Questar Auto Technologies, where he held the role of VP Finance and Head of FP&A. The filing also notes that Mr. Haim previously served as a controller at Evogene Ltd. between 2019 and 2022. The Form 6-K was signed by Ofer Haviv, President and Chief Executive Officer of Evogene Ltd.

What Was Disclosed

Evogene Ltd. reported the appointment of a new Board Chairperson, the resignation of its VP Finance for personal reasons, and the appointment of a replacement VP Finance, all effective in November 2026.